Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
26548 results about "Cell biology" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cell biology (also called cytology, from the Greek κύτος, kytos, "vessel") is a branch of biology that studies the structure and function of the cell, which is the basic unit of life. Cell biology is concerned with the physiological properties, metabolic processes, signaling pathways, life cycle, chemical composition, and interactions of the cell with their environment. This is done both on a microscopic and molecular level as it encompasses prokaryotic cells and eukaryotic cells. Knowing the components of cells and how cells work is fundamental to all biological sciences; it is also essential for research in bio-medical fields such as cancer, and other diseases. Research in cell biology is closely related to genetics, biochemistry, molecular biology, immunology, and cytochemistry. For some extra information, the recommendation is to check the biology resource in the external link.
Labelled nucleotides
InactiveUS7057026B2Use of techniqueBioreactor/fermenter combinationsBiological substance pretreatmentsOrganic chemistryNucleoside
Nucleosides and nucleotides are disclosed that are linked to detectable labels via a cleavable linker group.
Owner:ILLUMINA CAMBRIDGE LTD
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
InactiveUS6117679ALess immunogenicLibrary screeningDirected macromolecular evolutionMutated proteinNucleic acid sequencing
A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.
Owner:CODEXIS MAYFLOWER HLDG LLC
Activation and expansion of cells
Owner:LIFE TECH CORP
Regulation of endogenous gene expression in cells using zinc finger proteins
InactiveUS7013219B2Fusion with DNA-binding domainAntibody mimetics/scaffoldsZinc fingerGene expression
The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.
Owner:SANGAMO BIOSCIENCES INC
Methods and compositions for selecting siRNA of improved functionality
InactiveUS20050255487A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsGene silencingSilencing gene
Owner:THERMO FISHER SCIENTIFIC INC
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.
Owner:CODEXIS MAYFLOWER HLDG LLC
Methods of Analyzing Nucleic Acids from Individual Cells or Cell Populations
InactiveUS20150376609A1Facilitate hybridizationMicrobiological testing/measurementLibrary member identificationReagentNucleic acid
Methods, compositions and systems for analyzing individual cells or cell populations through the partitioned analysis of contents of individual cells or cell populations. Individual cells or cell populations are co-partitioned with processing reagents for accessing cellular contents, and for uniquely identifying the contents of a given cell or cell population, and subsequently analyzing the cell's contents and characterizing it as having derived from an individual cell or cell population, including analysis and characterization of the cell's nucleic acids through sequencing.
Owner:10X GENOMICS
Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
InactiveUS6027888AEfficient productionFold preciselyPeptide/protein ingredientsMicroorganismsDisulfide bondingZymogen
Disclosed are methods of producing eukaryotic disulfide bond-containing polypeptides in bacterial hosts, and compositions resulting therefrom. Co-expression of a eukaryotic foldase and a disulfide bond-containing polypeptide in a bacterial host cell is demonstrated. In particular embodiments, the methods have been used to produce mammalian pancreatic trypsin inhibitor and tissue plasminogen activator (tPA) in soluble, biologically-active forms, which are isolatable from the bacterial periplasm. Also disclosed are expression systems, recombinant vectors, and transformed host cells.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
InactiveUS6083715AEfficient productionFold preciselyBacteriaUnicellular algaeMolecular biologyDisulfide bond
Disclosed are methods and compositions for producing heterologous disulfide bond containing polypeptides in bacterial cells. In preferred embodiments the methods involve co-expression of a prokaryotic disulfide isomerase, such as DsbC or DsbG and a gene encoding a recombinant eukaryotic polypeptide. Exemplary polypeptides disclosed include tissue plasminogen activator.
Owner:GENENTECH INC +1
Labelled nucleotides
Owner:ILLUMINA CAMBRIDGE LTD
Methods for Producing Polypeptides by Regulating Polypeptide Association
ActiveUS20100015133A1Efficient productionEfficient formationAnimal cellsSugar derivativesHeterologousAntiendomysial antibodies
In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies.
Owner:CHUGAI PHARMA CO LTD
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
InactiveUS6165793ALess immunogenicDirected macromolecular evolutionImmunoglobulinsMutated proteinNucleotide
A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.
Owner:CODEXIS MAYFLOWER HLDG LLC
Lipid formulations for nucleic acid delivery
The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and / or administering the SNALP.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Methods and compositions for targeted cleavage and recombination
ActiveUS7888121B2High frequencyInhibitory activityFusion with DNA-binding domainHydrolasesPolynucleotideGenome
Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.
Owner:SANGAMO BIOSCIENCES INC
Lipid encapsulated interfering RNA
InactiveUS20060008910A1Inhibit aggregationReduce overexpressionBiocideOrganic active ingredientsLipid formationLipid particle
The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Modified siRNA molecules and uses thereof
ActiveUS20070135372A1Decrease immunostimulatory propertyImmunostimulatory activity of siRNA can be abolishedOrganic active ingredientsSugar derivativesLipid formationLipid particle
The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and / or modifying an siRNA having immunostimulatory properties are also provided.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Functional and hyperfunctional siRNA
ActiveUS20050246794A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsSilent geneGene silencing
Owner:THERMO FISHER SCIENTIFIC INC
Molecules with extended half-lives, compositions and uses thereof
InactiveUS20030190311A1High affinityExtended half-lifeCompounds screening/testingFungiIntravenous gammaglobulinIn vivo
The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Binding agents
Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
Owner:UCB SA +1
Antisense modulation of Smad6 expression
Antisense compounds, compositions and methods are provided for modulating the expression of Smad6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad6. Methods of using these compounds for modulation of Smad6 expression and for treatment of diseases associated with expression of Smad6 are provided.
Owner:IONIS PHARMA INC
Device and method for inhibiting release of pro-inflammatory mediator
InactiveUS20050075702A1Great flexibilityGreat specificitySpinal electrodesArtificial respirationNervous systemDrug
Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, to attenuate an immune response, including an inflammatory immune response, is discussed. Devices and systems to stimulate the sympathetic nervous system to attenuate an immune response are also discussed. Devices discussed include pulse generators and drug pumps. Systems are described as optionally having one or more sensors and operator instructions. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.
Owner:MEDTRONIC INC
Fc fusion proteins of human erythropoietin with increased biological activities
InactiveUS6900292B2Improve biological activityExtended serumPeptide/protein ingredientsAntibody mimetics/scaffoldsSide effectHalf-life
Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such HuEPO-L-vFc fusion proteins exhibit extended serum half-life and increased biological activities, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
Owner:LONGBIO PHARM (SUZHOU) CO LTD
Lipid encapsulated interfering RNA
ActiveUS20060240093A1Inhibit aggregationMetabolism disorderMicroencapsulation basedLipid formationLipid particle
Owner:ARBUTUS BIOPHARMA CORPORAT ION
In vitro evolution in microfluidic systems
ActiveUS20060078888A1High activitySpeed up the processSequential/parallel process reactionsFlow mixersGene productGenetic element
The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1
Apparatus for measurement and control of the content of glucose, lactate or other metabolites in biological fluids
InactiveUS6618603B2Immobilised enzymesBioreactor/fermenter combinationsMetaboliteGlucose Measurement
An apparatus for the continuous measurement of glucose and lactate in interstitial fluids including a glucose measurement cell, an A / D conversion block, a memory block and a bi-directional communication between the interface block and an external calculation unit.
Owner:A MENARINI IND FARM RIUNITE SRL
PDX1 expressing endoderm
InactiveUS20050266554A1Increase differentiationIncrease productionGastrointestinal cellsDiagnosticsGerm layerCell type
Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
Owner:CYTHERA
Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.
Owner:COGNATE BIOSERVICES
Lipid encapsulated interfering RNA
InactiveUS20050064595A1Inhibit aggregationMetabolism disorderMicroencapsulation basedLipid formationLipid particle
The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell.
Owner:PROTIVA BIOTHERAPEUTICS
Functional and hyperfunctional siRNA directed against Bcl-2
InactiveUS20050245475A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsSilencing geneCancer research
Owner:THERMO FISHER SCIENTIFIC INC
Pd-1 binding proteins
ActiveUS20110008369A1Enhance host anti-microbial immunityImprove immunityAntibody mimetics/scaffoldsImmunoglobulins against animals/humansPD-L1Host immunity
The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.
Owner:MERCK SHARP & DOHME LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com